Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		63 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (16,266)	$ (7,521)	$ 155,025
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	287	96
Non-cash interest expense	66	133
Non-cash accretion expense	117
Stock-based compensation and vesting of restricted stock	1,999	468
Deferred rent and lease incentive activity	(15)	(6)
Deferred taxes	(46)	(46)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	703	(360)
Other non-current assets	(7)	154
Accounts payable	1,104	175
Accrued expenses and other current liabilities	(455)	(1,399)
Other non-current liabilities		(125)
Settlement obligation	(488)
Deferred revenue	2,386	243
Net cash used in operating activities	(10,615)	(8,188)
Cash flows from investing activities:
Purchases of property and equipment	(70)
Net cash provided by investing activities	(70)
Cash flows from financing activities
Proceeds from the issuance of common stock, net of costs	18	48,027
Proceeds from the exercise of common stock options		245
Net cash used in financing activities	18	48,272
Non-cash activity
Effect of exchange rate on cash	17
Net increase (decrease) in cash and cash equivalents	(10,650)	40,084
Cash and cash equivalents - Beginning of period	31,515	21,462
Cash and cash equivalents - End of period	20,865	61,546	20,865
Supplemental disclosure of cash flow information
Issuance of common stock related to Bioceros acquisition (see Note 5)	5,000
Cash paid for interest	309	149
Cash paid for income taxes	3	$ 34
Supplemental schedule of non-cash investing and financing activities:
Amounts in accounts payable for capital expenditure	$ 595		$ 595